Poster B014: Cost Effective, In Vivo Syngeneic I/O Agent Screening Panel

MuScreen^™ Allows Profiling of Antitumor Efficacy and Biomarker Readout of Drug Candidates Using Well-Characterized Syngeneic Models

Ying Jin, Lan Zhang, Binchen Mao, Guoqin Zhai, Zhongliang Li, Meng Qiao, Annie An, Juan Zhang, Sheng Guo, WenQing Yang, and Qian Shi

In vitro cell-based screens frequently used in oncology to quickly identify responsive cells, often fail in immuno-oncology, due to immunotherapeutics targeting the complex host immune system.

While an in vivo screen using syngeneic models could be an alternative, this would usually be cost prohibitive. CrownBio has therefore developed the first cost-effective in vivo screening system to test novel immuno-oncology drug candidates utilizing multiple syngeneic models – MuScreen.

Cost effectiveness is afforded by test agents from multiple clients being run simultaneously during each screen, sharing vehicle and other common groups, which also reduces animal usage. Antitumor efficacy (via tumor growth inhibition) is evaluated as a final readout with optional FACS and IHC.

Read this Poster to Discover:

• A large scale murine syngeneic based platform which allows evaluation of test articles using 12 well-characterized mouse tumor models to determine drug efficacy, validated with anti-PD-1, PD-L1, and CTLA-4 data
  
  
• How basal levels of PD-L1 expression in tumors were found to be correlated with antitumor effects of an anti-PD-1 mAb in MuScreen, consistent with clinical observations
  
  
• That MuScreen represents a powerful in vivo screening platform for immuno-oncology drug evaluation, with the large data set obtained used to profile both antitumor response and immune-regulatory properties of test articles

Download the Poster Now!